Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC. Recently, emerging evidence has shown that ferroptosis, a newly discovered form of nonapoptotic cell death, is closely related to KRAS mutant cells. Here, we further investigated whether cetuximab-mediated regulation of p38/Nrf2/HO-1 promotes RSL3-induced ferroptosis and plays a pivotal role in overcoming drug resistance in KRAS mutant colorectal cancer (CRC). In our research, we used two KRAS mutant CRC cell lines, HCT116 and DLD-1, as models of intrinsic resistance to cetuximab. The viability of cells treated with the combination of RSL3 and cetuximab was assessed by the CCK-8 and colony formation assays. The effective of cetuximab to promote RSL3-induced ferroptosis was investigated by evaluating lipid reactive oxygen species accumulation and the expression of the malondialdehyde and the intracellular iron assay. Cetuximab therapy contributed to regulating the p38/Nrf2/HO-1 axis, as determined by western blotting and transfection with small interfering RNAs. Cetuximab promoted RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 in KRAS mutant CRC cells, and this was further demonstrated in a xenograft nude mouse model. Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells and that cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In KRAS mutant CRC cell lines and mouse CRC models, cetuximab promotes RSL3-induced ferroptosis by activating P38 MAPK to inhibit Nrf2/HO-1 signaling pathway [287].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [287]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691 · cited 3×
“Ferroptosis is characterized by irondependent accumulation [9].”
InfluentialCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689 · cited 1×
“INTRODUCTION Colorectal cancer (CRC) is the third most deadly cancer in the world [1, 2].”
BackgroundWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Treatment with cetuximab is ineffective in CRC patients with KRAS mutations [6, 7].”
BackgroundBroadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897 · cited 1×
“RAS-selective lethal 3 (RSL3), a small molecule, can kill RAS mutant cancer cells [10] and activate irondependent, nonapoptotic cell death of RAS mutant cancer cells [11].”
BackgroundNRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis
Dodson, M., Castro-Portuguez, R., & Zhang, D. D. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101107 · Cited by 2,435 · cited 1×
“Nuclear factor erythroid 2-related factor 2 (Nrf2), a dominant regulator of antioxidant transcription factors, prevents lipid peroxidation [13] and ferroptosis by increasing the transcription of multiple cytoprotective enzymes, such as haem oxygenase-1 (HO-1) [14].”
BackgroundYang, W. S., & Stockwell, B. R. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.02.010 · Cited by 1,876 · cited 1×
“RAS-selective lethal 3 (RSL3), a small molecule, can kill RAS mutant cancer cells [10] and activate irondependent, nonapoptotic cell death of RAS mutant cancer cells [11].”
BackgroundFerroptosis is a type of autophagy-dependent cell death
Zhou, B., Liu, J., Kang, R., Klionsky, D. J., Kroemer, G., & Tang, D. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.03.002 · Cited by 1,061 · cited 1×
“Cetuximab enhances RSL3-induced ferroptosis in KRAS mutant CRC cells RSL3 is a potent ferroptosis activator [20].”
BackgroundThe development of the concept of ferroptosis
Hirschhorn, T., & Stockwell, B. R. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.043 · Cited by 1,052 · cited 1×
“Ferroptosis is a newly discovered form of nonapoptotic cell death that is triggered via iron-dependent lipid peroxidation [8].”
BackgroundMetallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis
Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28574 · Cited by 703 · cited 1×
“Upregulation of MT-1G expression protects hepatocellular carcinoma cells from the effect of sorafenib and promotes cancer progression by inhibiting ferroptosis [36].”
Background
Cited by
Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer
Bae, T., Hallis, S. P., & Kwak, M.-K. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01180-8 · Cited by 354
“Similarly, cetuximab treatment facilitates RSL3-induced ferroptosis through the inhibition of NRF2/HO-1 signaling in KRAS -mutant colorectal cancer cells 180 .”
BackgroundChen, H., Qi, Q., Wu, N., Wang, Y., Feng, Q., Jin, R., & Jiang, L. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102426 · Cited by 163
Self-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Role of ferroptosis on tumor progression and immunotherapy
Gong, D., Chen, M., Wang, Y., Shi, J., & Hou, Y. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01218-8 · Cited by 175
Chen, W., Zhang, Y., Wang, Z., Tan, M., Lin, J., Qian, X., Li, H., & Jiang, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078205 · Cited by 145
“Cetuximab enhances RSL3induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK (Yang et al., 2021).”
Background
Metadata
- Authors
- Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L., & Ye, L.
- Affiliations
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Corresponding author
- Jiang, Lei
- Ye, Lechi
- Venue
- Cell Death & Disease
- Published
- 2021-11-13
- Volume
- 12
- Issue
- 11
- Pages
- 1079-1079
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC8590697
- OpenAlex
- W3212627135
- Semantic Scholar
- 896f76432716dd2a36727055f94f68e2243c1a69
- Cited by
- 300
- References
- 52
- Citations by year
- 2026: 42 · 2025: 65 · 2024: 79 · 2023: 79 · 2022: 35
- FWCI
- 31.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81572291)
- Natural Science Foundation of Zhejiang Province (LY19H160022)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- cetuximab, ferroptosis, RSL3, p38 MAPK, KRAS mutation, colorectal cancer, drug resistance, combination therapy, lipid reactive oxygen species, intracellular iron, HCT116 cells, DLD-1 cells
- MeSH terms
- Cetuximab, Antineoplastic Agents, Immunological, Ferroptosis, Animals, Carbolines, Humans, Mice, Nude, Transfection, Colorectal Neoplasms, Signal Transduction, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, NF-E2-Related Factor 2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. https://app.cochat.ai/papers/10.1038/s41419-021-04367-3
- The paper
- Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., Jiang, L., & Ye, L. (2021). Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death & Disease. https://doi.org/10.1038/s41419-021-04367-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.